YOLFTbeta
Viridian Therapeutics Inc

Viridian Therapeutics Inc

VRDN · NASDAQ · Healthcare / Biotechnology

30.87USD+0.39 (+1.28%)

Price History

Full chart

Market Stats

Previous Close30.48
Open30.24
Day Range29.81 – 30.96
52-Week Range13.18 – 34.29
Volume1.20M
Market Cap2.75B
P/E (TTM)0.00
Forward P/E1.01
EPS-3.39
Dividend Yield0.00%
Beta1.10
50-Day Avg21.65
200-Day Avg21.84

About

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Stephen F. Mahoney J.D., MBA
  • Employees252
  • Headquarters221 Crescent Street, Waltham, MA, United States, 02453, USA
  • Websitehttps://www.viridiantherapeutics.com

Leadership

  • Mr. Stephen F. Mahoney J.D., MBACEO, President & Director · b. 1971
  • Mr. Seth HarmonChief Financial Officer · b. 1981
  • Mr. Thomas W. Beetham J.D., MBAChief Operating Officer · b. 1970
  • Ms. Jennifer Tousignant J.D.Chief Legal Officer & Corporate Secretary · b. 1973
  • Dr. Radhika Tripuraneni M.D., M.P.H.Chief Medical Officer · b. 1980
  • Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow M.D., Ph.D.Co-Founder & Member of the Scientific Advisory Board · b. 1945
  • Dr. Marvin H. Caruthers Ph.D.Co-Founder & Scientific Advisory Board Member · b. 1940
  • Mr. Vahe Bedian Ph.D.Co-Founder & Scientific Advisor
  • Ms. Melissa MannoChief Human Resources Officer

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.41M4.32M4.32M2.54M3.34M4.00M8.39M4.46M1.05M2.96M1.77M314.00K302.00K70.85M
Growth (%)--2.03%+0.08%-41.25%+31.48%+19.96%+109.49%-46.80%-76.46%+182.19%-40.20%-82.28%-3.82%+23359.93%
Cost of Revenue3.04M2.50M3.24M2.47M2.55M19.62M30.42M32.79M28.30M620.00K755.00K1.32M1.24M1.16M
Gross Profit1.36M1.82M1.08M66.00K789.00K-15.62M-22.04M4.46M-27.25M2.96M1.77M314.00K302.00K70.85M
Gross Margin30.95%42.11%24.93%2.60%23.64%-390.21%-262.76%100.00%-2595.62%100.00%100.00%100.00%100.00%100.00%
Operating Expense5.39M2.01M7.94M11.25M13.30M10.91M11.05M46.44M83.13M82.69M136.08M254.76M299.34M434.24M
Operating Income-4.03M-196.21K-6.87M-11.19M-12.51M-26.53M-33.08M-41.98M-110.38M-79.73M-134.30M-254.45M-299.04M-363.39M
Operating Margin-91.40%-4.55%-158.96%-440.78%-374.83%-662.80%-394.51%-941.02%-10512.38%-2690.79%-7579.23%-81035.03%-99018.21%-512.91%
EBITDA-3.88M-47.90K-6.72M-11.00M-12.24M-25.82M-31.55M-40.75M-40.28M-79.29M-129.13M-235.37M-266.36M-337.19M
EBITDA Margin-88.12%-1.11%-155.63%-433.53%-366.74%-645.04%-376.21%-913.47%-3836.19%-2676.00%-7287.42%-74957.01%-88199.67%-475.93%
Net Income-7.21M-2.16M-7.89M-11.33M-12.67M-26.51M-32.70M-41.87M-110.72M-79.41M-129.87M-237.73M-269.95M-342.60M
Net Income Margin-163.67%-50.03%-182.64%-446.34%-379.80%-662.30%-389.97%-938.65%-10544.29%-2680.16%-7329.23%-75711.46%-89387.09%-483.57%
R&D225.38K96.85K293.00K1.00M888.00K19.62M30.42M34.79M28.30M56.89M100.89M159.76M238.25M338.93M
R&D as % of Total Revenue5.12%2.24%6.78%39.48%26.61%490.21%362.76%779.96%2695.62%1919.88%5693.79%50880.57%78892.05%478.38%
Interest Expense1.59M1.96M1.02M141.00K95.00K383.00K873.00K835.00K508.00K3.00K486.00K1.85M3.05M4.95M
Interest Expense % of Total Revenue36.12%45.49%23.68%5.56%2.85%9.57%10.41%18.72%48.38%0.10%27.43%588.22%1008.61%6.98%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.78M3.67M8.09M12.90M4.26M52.48M66.15M30.26M131.25M203.71M435.09M490.42M742.40M899.42M
Total Liabilities24.22M1.65M2.10M2.49M4.58M13.97M14.80M14.51M11.22M15.99M40.03M48.40M70.76M177.25M
Total Equity-21.44M2.03M5.99M10.41M-326.00K38.51M51.34M15.75M120.04M187.72M395.06M442.02M671.64M722.17M
Cash112.53K209.35K5.12M10.83M3.34M47.44M32.61M24.85M45.90M42.30M155.58M102.83M99.59M212.38M
Total Debt22.63M697.06K80.00K1.10M1.04M9.92M10.30M8.30M455.00K1.04M5.26M21.05M21.09M50.69M
Net Debt22.52M487.72K-5.04M-9.73M-2.30M-37.52M-22.31M-16.54M-45.44M-41.26M-150.32M-81.78M-78.50M-161.69M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.22M-1.17M-2.21M-6.90M-7.23M-28.17M-26.84M-36.06M-29.78M-54.58M-93.84M-184.17M-232.32M-276.39M
Investing Cash Flow-119.43K5.68K-274.00K-95.00K-3.00K1.03M-29.91M28.23M-50.48M-74.29M-115.13M-94.25M-228.65M-37.56M
Financing Cash Flow5.81M1.26M7.40M12.71M-257.00K52.47M41.92M70.00K101.31M125.28M322.24M225.67M457.74M426.74M
Capital Expenditure106.91K4.77K266.00K123.00K3.00K246.00K445.00K84.00K42.00K338.00K797.00K898.00K511.00K495.00K
Free Cash Flow-6.33M-1.17M-2.48M-7.02M-7.23M-28.41M-27.29M-36.14M-29.82M-54.92M-94.64M-185.07M-232.83M-276.89M
Dividends Paid720.00K285.00K------44.00K--14.49M--
FCF to OCF101.72%100.41%112.02%101.78%100.04%100.87%101.66%100.23%100.14%100.62%100.85%100.49%100.22%100.18%
Dividend Paid to FCF-11.37%-24.31%-------0.15%---7.83%--

Earnings

Report DateAug 8, 2014Nov 14, 2014Mar 30, 2015May 14, 2015Aug 12, 2015Nov 12, 2015Mar 16, 2016May 16, 2016Aug 15, 2016Oct 26, 2016Mar 24, 2017May 10, 2017Aug 11, 2017Nov 8, 2017Mar 14, 2018May 9, 2018Aug 7, 2018Nov 7, 2018Mar 13, 2019May 8, 2019Aug 7, 2019Nov 7, 2019Mar 11, 2020May 7, 2020Aug 5, 2020Nov 10, 2020Mar 26, 2021May 6, 2021Aug 11, 2021Nov 5, 2021Mar 10, 2022May 12, 2022Aug 15, 2022Nov 14, 2022Mar 8, 2023May 9, 2023Aug 8, 2023Nov 13, 2023Feb 27, 2024May 8, 2024Aug 8, 2024Nov 12, 2024Feb 25, 2025May 6, 2025Aug 6, 2025Nov 5, 2025Feb 26, 2026May 5, 2026Aug 6, 2026Nov 4, 2026
EPS Estimate--11.25-87.75-81.00-87.75-83.25-81.00-63.00-41.62--3.45-3.60-7.05-5.70-4.76-3.67-4.35-4.76-4.62-5.16-5.45-4.44-3.78-2.88-2.47-1.99-1.03-0.76-1.40-1.34-0.99-1.08-0.90-1.01-0.72-1.02-1.26-1.24-1.03-1.10-0.92-1.05-1.04-0.96-0.98-0.82-0.90-1.08-0.97-1.08
EPS Actual-254.91-96.75-387.00-101.25-74.25-87.75-63.00-58.50-51.75-3.45-3.45-9.00-5.10-4.05-4.35-2.70-4.35-4.35-4.95-5.70-4.35-5.40-4.65-2.70-1.80-1.50-30.74-2.91-2.21-1.25-1.32-0.98-1.06-0.86-1.13-1.61-1.27-1.09-1.35-0.79-1.02-1.15-0.81-0.87-1.00-0.34-1.08-0.90-1.05-
Surprise--760.00%-341.03%-25.00%15.38%-5.41%22.22%7.14%-24.34%-0.00%-150.00%27.66%28.95%8.61%26.43%0.00%8.61%-7.14%-10.47%20.18%-21.62%-23.02%6.25%27.13%24.62%-2884.47%-282.89%-57.86%6.72%-33.33%9.26%-17.78%14.85%-56.94%-57.84%-0.79%12.10%-31.07%28.18%-10.87%-9.52%22.43%9.38%-2.04%58.54%-20.00%16.67%-8.25%-
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.75B
Enterprise Value2.11B
Trailing P/E0.00
Forward P/E1.01
Price / Sales38.66
Price / Book4.84
EPS-3.39
Book Value4.98
Revenue (TTM)71.13M
Gross Profit (TTM)-253.55M
EBITDA-404.73M
Profit Margin0.00%
Operating Margin-44460.56%
Return on Equity-65.74%
Return on Assets-30.16%
Shares Outstanding113.29M
Shares Float100.79M
Beta1.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 17 analystsTarget 36.20
  • Strong Buy
    14
  • Buy
    3

Ownership Breakdown

Institutions
126.75%
Insiders
0.17%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    16.60M14.66%
  • BlackRock Inc
    8.55M7.55%
  • Bellevue Group AG
    6.73M5.94%
  • Paradigm Biocapital Advisors LP
    6.72M5.93%
  • Kynam Capital Management, LP
    6.45M5.70%
  • State Street Corp
    6.12M5.41%
  • T. Rowe Price Associates, Inc.
    5.75M5.07%
  • Fairmount Funds Management LLC
    5.09M4.49%
  • Vanguard Capital Management, LLC
    4.58M4.04%
  • Deep Track Capital, LP
    3.59M3.17%
  • VR Adviser, LLC
    3.26M2.88%
  • Wellington Management Company LLP
    3.13M2.76%
  • Vanguard Portfolio Management, LLC
    2.75M2.43%
  • Geode Capital Management, LLC
    2.50M2.21%
  • venBio Select Advisor LLC
    2.50M2.21%
  • Baker Bros Advisors LP
    2.38M2.10%
  • Point72 Asset Management, L.P.
    2.34M2.07%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.36M2.97%
  • iShares Russell 2000 ETF
    2.59M2.29%
  • State Street® SPDR® S&P® Biotech ETF
    2.51M2.22%

Stock Splits

  • Nov 13, 20201:15
  • Nov 7, 20161:15